EPAS1 and myocardial ischemia: Together, these findings suggest that pharmacologic HIF activators (particularly for HIF2-alpha) or treatment with recombinant AREG could be used to prophylactically treat cardiac surgery patients to enhance myocardial ischemia tolerance, and thereby improve outcomes of these major surgical interventions.